<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596440</url>
  </required_header>
  <id_info>
    <org_study_id>805712</org_study_id>
    <secondary_id>NIH R01CA126969</secondary_id>
    <nct_id>NCT00596440</nct_id>
  </id_info>
  <brief_title>Assessment of a Teachable Moment for Smoking Cessation</brief_title>
  <acronym>TM</acronym>
  <official_title>Assessment of a Teachable Moment for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A teachable moment (TM) refers to life events or transitions, such as physician visits, early
      detection screening feedback, pregnancy, and hospitalization for, and diagnosis of, disease,
      that inspire health behavior change. Despite strong intuitive appeal of the TM concept and
      over 150 studies of interventions implemented in a TM, there has been little investigation of
      the influence of TMs for smoking, particularly for promoting smoking cessation among those
      indirectly affected by a TM (e.g., relatives of cancer patients). This prospective
      observational study using a matched-group design will assess whether a lung cancer diagnosis
      increases enrollment in a smoking cessation program and cessation, and reduces smoking, among
      the patient's relatives/spouse who smoke. We will compare enrollment in a cessation program
      and cessation and smoking rates in 2 groups of smokers: 1) relatives/spouses of
      newly-diagnosed lung cancer patients, and 2) relatives/spouses of patients with an orthopedic
      condition. We will also explore mediators and moderators of a lung cancer diagnosis as a TM.
      This study could clarify the TM concept for smoking cessation, shed light on the underlying
      mechanisms of TMs, and guide future development and implementation of TM-based smoking
      cessation interventions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accrual Rate (Eligibility Visit)</measure>
    <time_frame>week zero</time_frame>
    <description>Show rate to eligibility visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Smoking Cessation Rate</measure>
    <time_frame>week nine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Show Rate at First Treatment Session</measure>
    <time_frame>week one</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">234</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Relatives of Cancer Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Relatives of Orthopedic Patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal nicotine patch</intervention_name>
    <description>8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        One group will be relatives/spouses of newly-diagnosed lung or head and neck cancer
        patients and the second group will be relatives/spouses of orthopedic patients. All
        participants will be regular smokers (i.e., smoke 10 cigarettes/day on average).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A relative (i.e., sibling, parent, child, grandparent, aunt, uncle, cousin) or spouse
             of a newly-diagnosed lung or head and neck cancer patient or orthopedic patient (e.g.,
             arthritis, bone and joint infection, foot and ankle conditions, hand, wrist, and elbow
             conditions such as carpal tunnel syndrome, shoulder and elbow conditions, such as
             rotator cuff injury, and knee conditions, such as ligament damage repair);

          2. A regular smoker (i.e., smoke 10 cigarettes/day on average);

          3. Able to use NRT (see contraindications under Key Exclusion Criteria);

          4. Age 18 or older (to use NRT); and

          5. Living within ~50 miles of PENN (to allow for meetings at PENN).

        Exclusion Criteria:

          1. Cannot communicate in English;

          2. Have current alcohol abuse/dependence;

          3. Are or have been diagnosed with cancer, asthma, HIV, emphysema, or COPD;

          4. Have a current medical problem for which NRT is contraindicated such as uncontrolled
             hypertension (&gt; 150 over 90), unstable angina, heart attack or stroke within the past
             6 months, and liver and/or kidney failure in the last 6-months;

          5. Currently use monoamine oxidase inhibitors or benzodiazepines, anti-psychotics, and
             antidepressants, including bupropion;

          6. Are allergic to adhesive tape or latex, and

          7. Are a female who is pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Schnoll, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <results_first_submitted>May 27, 2015</results_first_submitted>
  <results_first_submitted_qc>May 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2015</results_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Robert Schnoll</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>teachable moment</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Relatives of Cancer Patients</title>
          <description>Relatives of Cancer Patients offered Transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling.</description>
        </group>
        <group group_id="P2">
          <title>Relatives of Orthopedic Patients</title>
          <description>Relatives of Orthopedic Patients offered transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Showed to Eligibility Visit</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Showed to First Treatment Session</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Relatives of Cancer Patients</title>
          <description>Relatives of Cancer Patients offered Transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling.</description>
        </group>
        <group group_id="B2">
          <title>Relatives of Orthopedic Patients</title>
          <description>Relatives of Orthopedic Patients offered transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="234"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="11.7"/>
                    <measurement group_id="B2" value="49.2" spread="11.7"/>
                    <measurement group_id="B3" value="47.0" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Accrual Rate (Eligibility Visit)</title>
        <description>Show rate to eligibility visit</description>
        <time_frame>week zero</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Relatives of Cancer Patients</title>
            <description>Relatives of Cancer Patients offered Transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling.</description>
          </group>
          <group group_id="O2">
            <title>Relatives of Orthopedic Patients</title>
            <description>Relatives of Orthopedic Patients offered transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Accrual Rate (Eligibility Visit)</title>
          <description>Show rate to eligibility visit</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Smoking Cessation Rate</title>
        <time_frame>week nine</time_frame>
        <population>The 129 participants represents a subset of the sample that participated in treatment. This subset of participants includes only those who attended eligibility session and participated in the week 9 follow-up. One oncology relative became ineligible immediately following completion of this counseling session and was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Relatives of Cancer Patients</title>
            <description>Relatives of Cancer Patients offered Transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling.</description>
          </group>
          <group group_id="O2">
            <title>Relatives of Orthopedic Patients</title>
            <description>Relatives of Orthopedic Patients offered transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Smoking Cessation Rate</title>
          <population>The 129 participants represents a subset of the sample that participated in treatment. This subset of participants includes only those who attended eligibility session and participated in the week 9 follow-up. One oncology relative became ineligible immediately following completion of this counseling session and was excluded.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Show Rate at First Treatment Session</title>
        <time_frame>week one</time_frame>
        <population>This analysis includes only a subset of participants who had not discontinued the study by week 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Relatives of Cancer Patients</title>
            <description>Relatives of Cancer Patients offered Transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling.</description>
          </group>
          <group group_id="O2">
            <title>Relatives of Orthopedic Patients</title>
            <description>Relatives of Orthopedic Patients offered transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Show Rate at First Treatment Session</title>
          <population>This analysis includes only a subset of participants who had not discontinued the study by week 1.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Relatives of Cancer Patients</title>
          <description>Relatives of Cancer Patients offered Transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling.</description>
        </group>
        <group group_id="E2">
          <title>Relatives of Orthopedic Patients</title>
          <description>Relatives of Orthopedic Patients offered transdermal nicotine patch: 8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg and behavioral counseling</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Schnoll</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7143</phone>
      <email>schnoll@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

